Due to the low incidence of hypoglycaemia associated with the incretin-based therapies the American Diabetes Association recommends GLP-1 receptor agonists for groups of patients particularly prone to hypoglycaemic episodes and for those groups in which hypoglycaemia is particularly undesirable. The gene discussed is GLP1R; the disease is diabetes mellitus.